Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer

Core Insights - Fate Therapeutics has appointed Kamal Adawi as Chief Financial Officer effective October 20, 2025, bringing over 20 years of financial leadership experience in the life sciences industry [1][2][3] Company Overview - Fate Therapeutics is a clinical-stage biopharmaceutical company focused on developing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies [4] - The company aims to create off-the-shelf cellular immunotherapies that are broadly accessible and require less intensive or no conditioning chemotherapy, potentially transforming treatment for autoimmune diseases and cancer [3][4] Leadership Appointment - Kamal Adawi's previous experience includes serving as CFO for Mindera Health and Exagen Inc., where he led Exagen through a successful IPO [2][3] - His expertise includes financial strategy, capital formation, and operational growth, which will support the company's clinical programs, particularly the development of FT819 for systemic lupus erythematosus (SLE) [2][3] Stock Options and Awards - As part of his employment, Mr. Adawi will receive an option to purchase 375,000 shares of common stock, vesting over four years, and an award of 75,000 restricted stock units, also subject to vesting conditions [3]